Managing meal-time glucose spikes remains an elusive goal for many insulin-treated patients with diabetes. ARE 001 aims to put an end to "swings and roudabouts" and the catch-up cycle of high blood glucose peaks and hypoglycaemic valleys.
Patients with morbid obesity face severe restrictions in activities of daily living. ARE 002 is foreseen to be an oral agent that leads to noteworthy sustained weight loss.
Type 2 Diabetes mellitus is the leading cause of blindness and end-stage renal disease in adults. It is characterized by a progressive loss in insulin secretion. ARE 003 promises to protect islet function making it the first truly disease-modifying oral anti-diabetic agent.
Aside from physical barriers and abstinence there are no means for contraception targeted at males available today. ARE 004 is intended as a safe reversible pharmacological contraceptive for men.